TRUMF
Terumo Corporation
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Buy
+51/100
Last price
15.14
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
15.14
Day high
14.38
Day low
14.38
Volume
197
Market cap
$22.33B
P/E (TTM)
24.82
52W range
11.49 – 18.60
Trailing performance
Returnvs SPY
1W
+4.27%
+2.5%
1M
+5.29%
+4.0%
3M
+8.14%
+4.9%
6M
+15.66%
+0.9%
YTD
+14.96%
+1.2%
1Y
-9.88%
-25.4%
3Y
+11.94%
-69.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TRUMF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
33.75M
Total on file
Fundamentals
Market cap$22.33B
Enterprise value$145.75B
Revenue (TTM)$1.18T
Gross profit$629.99B
EBITDA$305.71B
Net income$164.50B
EPS (TTM)$0.61
Free cash flow$95.83B
Total cash$314.63B
Total debt$438.06B
Book value / share$7.08
Shares outstanding1.48B
Float1.45B
Short % of float—
Dividend yield1.51%
Beta (5Y)0.31
Valuation & profitability ratios
Trailing P/E24.82
Forward P/E—
PEG ratio2.18
Price / sales—
Price / book2.14
EV / revenue0.12
EV / EBITDA0.48
Gross margin53.22%
Operating margin28.70%
Profit margin13.90%
Return on equity10.85%
Return on assets6.92%
Debt / equity26.36
Current ratio2.19
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.13T | $1.04T | $921.86B | $820.21B | +9.2% |
| Operating revenue | $1.13T | $1.04T | $921.86B | $820.21B | +9.2% |
| Cost of revenue | $537.20B | $475.50B | $442.69B | $402.84B | +13.0% |
| Gross profit | $594.67B | $560.67B | $479.17B | $417.37B | +6.1% |
| Selling, general & admin | $409.94B | $381.65B | $344.98B | $299.86B | +7.4% |
| Total operating expense | $418.35B | $403.00B | $339.08B | $300.04B | +3.8% |
| Operating income | $176.32B | $157.67B | $140.09B | $117.33B | +11.8% |
| Net interest income | $2.96B | -$2.62B | $754.00M | -$1.37B | +212.9% |
| Pre-tax income | $178.25B | $154.57B | $140.83B | $116.14B | +15.3% |
| Tax provision | $42.34B | $37.59B | $34.45B | $26.81B | +12.6% |
| Net income | $135.91B | $116.98B | $106.37B | $89.33B | +16.2% |
| Net income to common | $135.91B | $116.98B | $106.37B | $89.33B | +16.2% |
| Basic EPS | 92.14 | 79.01 | 71.50 | 59.50 | +16.6% |
| Diluted EPS | 92.12 | 78.99 | 71.47 | 59.48 | +16.6% |
| EBIT | $181.54B | $160.82B | $143.60B | $120.15B | +12.9% |
| EBITDA | $276.92B | $246.27B | $220.35B | $190.39B | +12.4% |
| Basic shares | 1.48B | 1.48B | 1.49B | 1.49B | -0.4% |
| Diluted shares | 1.48B | 1.48B | 1.49B | 1.50B | -0.4% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $280.49B | $221.87B | $204.88B | $187.32B | +26.4% |
| Cash & short-term investments | $280.73B | $222.26B | $231.04B | $187.43B | +26.3% |
| Accounts receivable | $214.93B | $176.85B | $178.71B | $150.63B | +21.5% |
| Inventory | $335.63B | $294.38B | $286.60B | $249.62B | +14.0% |
| Total current assets | $861.04B | $723.50B | $722.12B | $611.40B | +19.0% |
| Property, plant & equipment | $506.48B | $431.08B | $415.85B | $370.87B | +17.5% |
| Goodwill & intangibles | $803.41B | $545.24B | $588.23B | $538.21B | +47.3% |
| Total assets | $2.31T | $1.83T | $1.83T | $1.60T | +26.5% |
| Total current liabilities | $540.73B | $240.97B | $379.15B | $218.00B | +124.4% |
| Current debt | $279.89B | $15.00B | $156.87B | $11.22B | +1,765.9% |
| Long-term debt | $99.91B | $159.84B | $74.98B | $220.71B | -37.5% |
| Total debt | $379.80B | $174.84B | $231.85B | $231.94B | +117.2% |
| Total liabilities | $727.73B | $459.86B | $504.31B | $491.16B | +58.2% |
| Retained earnings | $1.12T | $1.02T | $954.68B | $874.27B | +9.9% |
| Shareholder equity | $1.58T | $1.37T | $1.33T | $1.11T | +15.8% |
| Working capital | $320.31B | $482.53B | $342.96B | $393.39B | -33.6% |
| Net tangible assets | $781.10B | $823.29B | $738.87B | $572.85B | -5.1% |
| Shares issued | 1.48B | 1.48B | 1.49B | 1.50B | 0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $178.25B | $154.57B | $140.83B | $116.14B | +15.3% |
| Depreciation & amortisation | $95.38B | $85.45B | $76.75B | $70.24B | +11.6% |
| Change in working capital | -$27.43B | -$14.26B | -$29.86B | -$35.84B | -92.3% |
| Operating cash flow | $230.85B | $210.80B | $146.33B | $117.54B | +9.5% |
| Capital expenditure | -$101.96B | -$82.36B | -$78.77B | -$72.17B | -23.8% |
| Investing cash flow | -$344.10B | -$82.48B | -$81.47B | -$59.12B | -317.2% |
| Share buybacks | -$1.00M | -$30.05B | -$11.11B | -$50.09B | +100.0% |
| Dividends paid | -$41.29B | -$35.62B | -$32.01B | -$27.90B | -15.9% |
| Financing cash flow | $155.50B | -$108.77B | -$62.08B | -$86.56B | +243.0% |
| Free cash flow | $128.89B | $128.44B | $67.56B | $45.36B | +0.4% |
| End cash position | $280.49B | $221.87B | $204.88B | $187.32B | +26.4% |
| Line item | 2026-06-30 | 2025-06-30 | YoY |
|---|---|---|---|
| Basic EPS | 47.74 | 28.37 | +68.3% |
| Diluted EPS | 47.73 | — | — |
| Basic shares | 1.48B | — | — |
| Diluted shares | 1.48B | — | — |
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $280.49B | $217.16B | $221.87B | +29.2% |
| Cash & short-term investments | $280.73B | $217.29B | $222.26B | +29.2% |
| Accounts receivable | $214.93B | $188.22B | $176.85B | +14.2% |
| Inventory | $335.63B | $311.91B | $294.38B | +7.6% |
| Total current assets | $861.04B | $744.08B | $723.50B | +15.7% |
| Property, plant & equipment | $506.48B | $471.09B | $431.08B | +7.5% |
| Goodwill & intangibles | $803.41B | $543.62B | $545.24B | +47.8% |
| Total assets | $2.31T | $1.89T | $1.83T | +22.0% |
| Total current liabilities | $540.73B | $296.30B | $240.97B | +82.5% |
| Current debt | $279.89B | $59.99B | $15.00B | +366.6% |
| Long-term debt | $99.91B | $99.89B | $159.84B | +0.0% |
| Total debt | $379.80B | $159.87B | $174.84B | +137.6% |
| Total liabilities | $727.73B | $457.29B | $459.86B | +59.1% |
| Retained earnings | $1.12T | $1.07T | $1.02T | +4.0% |
| Shareholder equity | $1.58T | $1.44T | $1.37T | +10.2% |
| Working capital | $320.31B | $447.78B | $482.53B | -28.5% |
| Net tangible assets | $781.10B | $893.92B | $823.29B | -12.6% |
| Shares issued | 1.48B | 1.48B | 1.48B | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $307.69B | +11.9% |
| Next quarter | — | — | $323.88B | +9.2% |
| Current year | — | — | $1.26T | +179.0% |
| Next year | — | — | $1.34T | +6.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders2.29%
Held by institutions67.82%
Institutions holding366
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
14.24
+6.30% from price
SMA 20
14.43
+4.90% from price
SMA 50
14.72
+2.89% from price
SMA 100
14.11
+7.32% from price
SMA 200
13.64
+11.00% from price
EMA 12
14.46
+4.71% from price
EMA 26
14.52
+4.24% from price
EMA 50
14.48
+4.58% from price
RSI (14)
57.0
Neutral
MACD (12,26,9)
-0.06
Hist 0.09
ATR (14)
0.37
2.44% of price
Realised vol 30D
55.2%
Annualised
Bollinger upper
15.42
20, 2σ
Bollinger lower
13.45
20, 2σ
50 / 200 cross
Golden
14.72 vs 13.64
Trend bias
Above 200
+11.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.62
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
55.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-34.7%
Peak to trough
Max drawdown 5Y
-49.9%
Peak to trough
ATR 14
0.37
2.44% of price
Beta (reported)
0.31
5Y monthly, from filing
Dividends & splits
Forward rate$0.23 / yr
Forward yield1.51%
5-year avg yield0.93%
Payout ratio32.57%
Ex-dividend dateMar 30, 2027
Next pay dateJun 24, 2019
Last split2:1
Split dateMar 28, 2024
Headlines
Terumo Corp's Dividend Analysis
GuruFocus.com · 8d ago
Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031
GlobeNewswire · 19d ago
Vascular Access Device Market by Type, Route of Insertion, Application, End User - Global Forecast to 2031
GlobeNewswire · 19d ago
NICE Supports Routine NHS Funding and Access to Ex-Situ Machine Perfusion in a Major Step Forward for Liver Transplantation
GlobeNewswire · 47d ago
Terumo Corp (TRUMF) (Q1 2027) Earnings Call Highlights: Record Revenue and Profit Surge on ...
GuruFocus.com · 57d ago
Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated Technologies
GlobeNewswire · 75d ago
Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway
Zacks · 78d ago
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Zacks · 79d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.